Form 4: Protara CEO Sells Shares for Tax Obligations

Protara Therapeutics CEO Jesse Shefferman reported the sale of 8,732 common shares to cover tax liabilities related to a restricted stock unit award vesting.

Summary

• Jesse Shefferman, CEO and President of Protara Therapeutics, Inc. (TARA), reported a transaction involving company common stock.
• On January 26, 2026, Shefferman disposed of 8,732 shares of common stock at a price of $6.67 per share.
• This disposal was a 'tax withholding' transaction (Code F), where shares were withheld by the issuer to satisfy income tax obligations.
• The tax obligations arose from the vesting of a Restricted Stock Unit (RSU) Award granted to Shefferman on January 24, 2025.
• Following this transaction, Shefferman directly beneficially owns 1,021,832 shares of Protara Therapeutics common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction by an insider to cover tax liabilities associated with the vesting of a restricted stock unit award. This type of transaction is a standard part of executive compensation and does not typically indicate a positive or negative sentiment regarding the company's future prospects.

Future Outlook

N/A

Industry Context

This Form 4 filing details a routine insider transaction related to compensation and tax obligations, which is common across all industries for executives receiving equity awards. It does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes and does not reflect a change in management's confidence or strategic direction.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Protara Therapeutics, TARA, Jesse Shefferman, Form 4, Insider transaction, Stock sale, Tax withholding, Restricted Stock Unit, CEO, Beneficial ownership